STATE-OF-THE-ART PAPER
Enhanced external counterpulsation for ischemic heart disease
Whats behind the curtain?
Piero O. Bonetti, MD*,
David R. Holmes, Jr, MD, FACC*,
Amir Lerman, MD, FACC* and
Gregory W. Barsness, MD, FACC*,*
* Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota, USA.
Manuscript received August 1, 2002;
revised manuscript received February 21, 2003,
accepted February 27, 2003.
* Reprint requests and correspondence: Dr. Gregory W. Barsness, Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA. barsness.gregory{at}mayo.edu
Enhanced external counterpulsation (EECP) has been shown to reduce angina and to improve objective measures of myocardial ischemia in patients with refractory angina. Prospective clinical studies and large treatment registries suggest that a course of EECP is associated with prolongation of the time to exercise-induced ST-segment depression and resolution of myocardial perfusion defects, as well as with enhanced exercise tolerance and quality of life. With a growing knowledge base supporting the safety and beneficial clinical effects associated with EECP, this therapy can be considered a valuable treatment option, particularly in patients who have exhausted traditional revascularization methods and yet remain symptomatic despite optimal medical care. However, although the concept of external counterpulsation was introduced almost four decades ago, and despite growing evidence supporting the clinical benefit and safety of this therapeutic modality, little is firmly established regarding the mechanisms responsible for the beneficial effects associated with this technique. Suggested mechanisms contributing to the clinical benefit of EECP include improvement in endothelial function, promotion of coronary collateralization, enhancement of ventricular function, peripheral effects similar to those observed with regular physical exercise, and nonspecific placebo effects. This review summarizes the current evidence for a contribution of these mechanisms to the clinical benefit associated with EECP.
|
Abbreviations and Acronyms
| | ANP | | atrial natriuretic peptide | | BNP | | brain natriuretic peptide | | CAD | | coronary artery disease | | EECP | | enhanced external counterpulsation | | HGF | | hepatocyte growth factor | | IEPR | | International Enhanced External Counterpulsation Patient Registry | | LV | | left ventricular | | LVEF | | left ventricular ejection fraction | | MUST-EECP | | Multicenter Study of Enhanced External Counterpulsation | | NO | | nitric oxide | | VEGF | | vascular endothelial growth factor |
|
This article has been cited by other articles:

|
 |

|
 |
 
M. Esmaeilzadeh, A. Khaledifar, M. Maleki, A. Sadeghpour, N. Samiei, H. Moladoust, F. Noohi, Z. O. Haghighi, and A. Mohebbi
Evaluation of left ventricular systolic and diastolic regional function after enhanced external counter pulsation therapy using strain rate imaging
Eur J Echocardiogr,
January 1, 2009;
10(1):
120 - 126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. W. Alexandrov, M. Ribo, K. S. Wong, R. M. Sugg, Z. Garami, J. T. Jesurum, B. Montgomery, and A. V. Alexandrov
Perfusion Augmentation in Acute Stroke Using Mechanical Counter-Pulsation-Phase IIa: Effect of External Counterpulsation on Middle Cerebral Artery Mean Flow Velocity in Five Healthy Subjects
Stroke,
October 1, 2008;
39(10):
2760 - 2764.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Han, T. W. Leung, W. W. Lam, Y. O. Soo, A. W. Alexandrov, V. Mok, Y.-F. V. Leung, R. Lo, and K. S. Wong
Preliminary Findings of External Counterpulsation for Ischemic Stroke Patient With Large Artery Occlusive Disease
Stroke,
April 1, 2008;
39(4):
1340 - 1343.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Wu, Z. Du, C. Hu, Z. Zheng, C. Zhan, H. Ma, D. Fang, K. T. Ahmed, R. J. Laham, J. C. K. Hui, et al.
Angiogenic effects of long-term enhanced external counterpulsation in a dog model of myocardial infarction
Am J Physiol Heart Circ Physiol,
January 1, 2006;
290(1):
H248 - H254.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Lerman and A. M. Zeiher
Endothelial Function: Cardiac Events
Circulation,
January 25, 2005;
111(3):
363 - 368.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P.W Serruys and J Aoki
Therapeutic options for patients with chronic myocardial ischaemia
Eur. Heart J. Suppl.,
September 1, 2004;
6(suppl_E):
E2 - E11.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
P. O. Bonetti, S. N. Gadasalli, A. Lerman, and G. W. Barsness
Successful Treatment of Symptomatic Coronary Endothelial Dysfunction With Enhanced External Counterpulsation
Mayo Clin. Proc.,
May 1, 2004;
79(5):
690 - 692.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Berger
Ranolazine and Other Antianginal Therapies in the Era of the Drug-Eluting Stent
JAMA,
January 21, 2004;
291(3):
365 - 367.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Vita and G. F. Mitchell
Effects of shear stress and flow pulsatility on endothelial function: Insights gleaned from external counterpulsation therapy
J. Am. Coll. Cardiol.,
December 17, 2003;
42(12):
2096 - 2098.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Enhanced External Counterpulsation -- What's the Mechanism of Benefit?
Journal Watch (General),
June 27, 2003;
2003(627):
4 - 4.
[Full Text]
|
 |
|
|